Deep Health AI India Ltd (539559)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Deep Health's revenue was ₹0.5 Cr (+200.0% year on year, +80.0% on the previous quarter), and net profit ₹-2.1 Cr (against a profit a year earlier); the operating margin was -457.1%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹0.5 | +200.0% | +80.0% |
| Operating profit | ₹-2.1 | loss widened | to loss |
| Net profit | ₹-2.1 | to loss | loss narrowed |
| EPS (₹) | -0.15 | to loss | loss narrowed |
| Operating margin | -457.1% | — | — |
📢 Recent Corporate Announcements
Deep Health AI India Ltd's Board approved the acquisition of debt owed by Sparion Infrastructure Private Limited from Kshitij Polyline Limited for ₹10.35 Cr. The transaction will be executed via a Deed of Assignment on an 'as is where is' and 'without recourse' basis. The acquisition includes underlying security, specifically a pledge of 4,900 equity shares (49% stake) of Sparion Infrastructure. Relative to Deep Health AI's TTM revenue of ₹5 Cr and net worth of ₹52 Cr, this assignment represents a significant capital commitment of over 200% of annual revenue.
- Assignment consideration stands at ₹10,35,35,520/-
- Debt is acquired from Assignor M/s. Kshitij Polyline Limited owed by Sparion Infrastructure Private Limited
- Underlying security includes pledge of 4,900 equity shares representing 49% equity shareholding of Sparion Infrastructure Private Limited
- Assignment terms are on an 'as is where is', 'as is what is', and 'without recourse' basis
Deep Health AI India Ltd's Board approved the acquisition of debt owed by Sparion Infrastructure Private Limited from Kshitij Polyline Limited for ₹10.35 Cr. The transaction will be executed via a Deed of Assignment on an 'as is where is' and 'without recourse' basis. The acquisition includes underlying security, specifically a pledge of 4,900 equity shares (49% stake) of Sparion Infrastructure. Relative to Deep Health AI's TTM revenue of ₹5 Cr and net worth of ₹52 Cr, this assignment represents a significant capital commitment of over 200% of annual revenue.
- Assignment consideration stands at ₹10,35,35,520/-
- Debt is acquired from Assignor M/s. Kshitij Polyline Limited owed by Sparion Infrastructure Private Limited
- Underlying security includes pledge of 4,900 equity shares representing 49% equity shareholding of Sparion Infrastructure Private Limited
- Assignment terms are on an 'as is where is', 'as is what is', and 'without recourse' basis
Deep Health AI India Ltd's Board approved the acquisition of debt owed by Sparion Infrastructure Private Limited from Kshitij Polyline Limited for ₹10.35 Cr. The transaction will be executed via a Deed of Assignment on an 'as is where is' and 'without recourse' basis. The acquisition includes underlying security, specifically a pledge of 4,900 equity shares (49% stake) of Sparion Infrastructure. Relative to Deep Health AI's TTM revenue of ₹5 Cr and net worth of ₹52 Cr, this assignment represents a significant capital commitment of over 200% of annual revenue.
- Assignment consideration stands at ₹10,35,35,520/-
- Debt is acquired from Assignor M/s. Kshitij Polyline Limited owed by Sparion Infrastructure Private Limited
- Underlying security includes pledge of 4,900 equity shares representing 49% equity shareholding of Sparion Infrastructure Private Limited
- Assignment terms are on an 'as is where is', 'as is what is', and 'without recourse' basis
Deep Health AI India reported a standalone net loss of Rs 1.90 crore for the quarter ended June 30, 2026, a sharp decline from a profit of Rs 0.09 crore in the year-ago period. While revenue from operations grew 200% YoY to Rs 45 lakhs, it was entirely driven by the pharmaceutical segment as the jewellery business reported zero revenue. The bottom line was weighed down by a significant spike in 'Other Expenses' totaling Rs 2.46 crore, which exceeded total income by over 4x. Despite the operational loss, a high Other Comprehensive Income of Rs 6.89 crore led to a Total Comprehensive Income of Rs 4.99 crore.
- Revenue from operations increased to Rs 45.00 lakhs from Rs 15.00 lakhs in the same quarter last year.
- Net loss for the quarter stood at Rs 189.90 lakhs compared to a profit of Rs 9.33 lakhs YoY.
- Other expenses surged to Rs 245.88 lakhs, significantly impacting the operating margins.
- Pharmaceutical segment contributed 100% of the Rs 45.00 lakhs revenue from operations, with zero revenue from Jewellery.
- Total Comprehensive Income reached Rs 499.12 lakhs, bolstered by a Rs 689.02 lakh gain in Other Comprehensive Income.
Deep Health AI India Ltd (formerly Deep Diamond India) reported a standalone net loss of ₹1.90 crore for Q1 FY27, a sharp decline from a profit of ₹0.09 crore in Q1 FY26. While revenue from operations grew 200% YoY to ₹45 lakhs, it was entirely offset by a surge in 'Other Expenses' which reached ₹2.46 crore. The company has effectively pivoted to the Pharmaceutical segment, which contributed 100% of operational revenue, while the legacy Jewellery business reported zero revenue. Despite the operational loss, a significant Other Comprehensive Income (OCI) of ₹6.89 crore led to a Total Comprehensive Income of ₹4.99 crore.
- Revenue from operations increased to ₹45.00 lakhs in Q1 FY27 from ₹15.00 lakhs in Q1 FY26.
- Net loss for the quarter stood at ₹189.90 lakhs compared to a profit of ₹9.33 lakhs in the same period last year.
- Other expenses spiked to ₹245.88 lakhs, representing 546% of the quarter's revenue from operations.
- Pharmaceutical segment revenue grew to ₹45.00 lakhs, while the Jewellery segment recorded ₹0 revenue.
- Total Comprehensive Income reached ₹499.12 lakhs, primarily driven by ₹689.02 lakhs in Other Comprehensive Income.
Deep Health AI India Ltd (formerly Deep Diamond India Limited) has scheduled a board meeting for August 13, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. This follows a volatile FY26 where the company reported a TTM revenue of Rs 4 Cr and a significant net loss of Rs 4.51 Cr in the most recent March 2026 quarter. The company is a micro-cap with a market capitalization of Rs 25 Cr and negligible promoter holding at 0.03%. The trading window for insiders has been closed since July 01, 2026.
- Board meeting scheduled for August 13, 2026, to approve Q1 FY27 results.
- Trading window closed from July 01, 2026, until 48 hours after the results declaration.
- Company reported a net loss of Rs 4.51 Cr in the previous quarter ended March 2026.
- Promoter holding remains critically low at 0.03% as of June 2026.
Deep Health AI India Ltd (formerly Deep Diamond India Ltd) has received shareholder approval for the appointment of two Non-Executive Independent Directors. Mr. Bhupesh Swami, who has 20 years of experience in logistics and export-import, has been appointed for a 2-year term effective July 02, 2026. Mrs. Shashi Kala Dhabriya has been appointed for a 5-year term effective March 20, 2026. These appointments occur within a micro-cap company (Rs 26 Cr market cap) characterized by an exceptionally low promoter holding of 0.03%.
- Appointment of Mr. Bhupesh Swami for a 2-year term ending July 01, 2028
- Appointment of Mrs. Shashi Kala Dhabriya for a 5-year term ending March 19, 2031
- Shareholder approval obtained at the Extra-Ordinary General Meeting held on July 30, 2026
- Company maintains a very small scale with TTM revenue of only Rs 4 Cr
- Promoter holding remains negligible at 0.03% as of June 2026
Deep Health AI India Ltd (formerly Deep Diamond India Ltd) has disclosed a delayed update regarding the acquisition of 49,100 sq. mtr. of land in Pune, Maharashtra. The company has paid an aggregate advance of Rs 2.85 crore in 10 tranches to Elegant Floriculture & Agrotech (India) Limited, with the final payment made on June 06, 2026. This acquisition marks a strategic shift toward wellness and agro-tourism, including a naturopathy centre and medicinal plant cultivation. The disclosure was delayed by over four months from the initial MoU date of March 06, 2026, which the company attributed to an administrative oversight.
- Advance payment of Rs 2,85,00,000 (Rs 2.85 Cr) made for land acquisition
- Land area totals 49,100 sq. mtr. located in Maval, Pune, Maharashtra
- MoU signed on March 06, 2026, with the final advance tranche paid on June 06, 2026
- Project focus includes a naturopathy centre and cultivation of medicinal plant species
- Disclosure made on July 13, 2026, following a delay from the original March 2026 MoU date
Deep Health AI India Ltd (formerly Deep Diamond India Limited) has submitted a revised Auditor's Report for the financial year ended March 31, 2026. The revision addresses an inadvertent omission in the original report submitted on May 29, 2026, which failed to list the specific entities included in the consolidated financial statements. The company has explicitly stated that this correction has no impact on the reported financial figures or the audit opinion. The standalone and consolidated results remain identical to those previously disclosed.
- Original financial results for FY26 were approved by the Board on May 29, 2026
- Revised Auditor's Report submitted on July 13, 2026, to include names of consolidated entities
- Company confirms 0% change in the Audited Standalone and Consolidated Financial Results
- The omission was described as purely inadvertent with no impact on the audit opinion
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
